Back Article

Ye M, Xu L, Lu F, Chen L, Hu C, et al. 2024. Hypoxia drives CBR4 down-regulation promotes gastroenteropancreatic neuroendocrine tumors via activation mammalian target of rapamycin mediated by fatty acid synthase. Journal of Cell Communication and Signaling 18(3):e12041

Gao H, Zhang W, Li Z, Liu W, Liu M, et al. 2024. Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide. BMC Cancer 24(1):1362

Dhakre VW, Galande ST, Patil VG, Shah NC, Rathod C, et al. 2023. Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas: what do we know, what have we learnt? Gastrointestinal Tumors 10(1):14−18

Ye Z, Zhou Y, Hu Y, Li Q, Xu Z, et al. 2024. Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under genomic instability and histological grading. iScience 27(9):110836

Ye M, Lu F, Gu D, Xue B, Xu L, et al. 2024. Hypoxia exosome derived CEACAM5 promotes tumor-associated macrophages M2 polarization to accelerate pancreatic neuroendocrine tumors metastasis via MMP9. FASEB Journal 38(13):e23762

Gopalakrishnan G, Srinivas BH, Pottakkat B, Gnanasekaran S, Kalayarasan R. 2021. Perforated high-grade mixed neuroendocrine nonneuroendocrine neoplasm of cecum: unusual presentation of rare disease. Gastrointestinal Tumors 8(3):128−33

Xu Z, Wang L, Dai S, Chen M, Li F, et al. 2021. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Network Open 4(9):e2124750

Gallo C, Rossi RE, Cavalcoli F, Barbaro F, Boškoski I, et al. 2022. Rectal neuroendocrine tumors: current advances in management, treatment, and surveillance. World Journal of Gastroenterology 28(11):1123−38

Cope J, Srirajaskanthan R. 2022. Rectal neuroendocrine neoplasms: why is there a global variation? Current Oncology Reports 24(3):257−63

Hu P, Bai J, Liu M, Xue J, Chen T, et al. 2020. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer 23(4):591−99

Kasajima A, Pfarr N, Mayr EM, Ura A, Moser E, et al. 2024. Rapid evolution of metastases in patients with treated G3 neuroendocrine tumors associated with NEC-like transformation and TP53 mutation. Endocrine Pathology 35(4):313−24

Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, et al. 2021. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer 29(1):1−14

de Visser KE, Joyce JA. 2023. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41(3):374−403

Chen W, Zhou M, Guan B, Xie B, Liu Y, et al. 2024. Tumour-associated macrophage-derived DOCK7-enriched extracellular vesicles drive tumour metastasis in colorectal cancer via the RAC1/ABCA1 axis. Clinical and Translational Medicine 14(2):e1591

Choi JS, Kim MJ, Shin R, Park JW, Heo SC, et al. 2024. Risk factor analysis of lymph node metastasis for rectal neuroendocrine tumors: who needs a radical resection in rectal neuroendocrine tumors sized 1–2 cm? Annals of Surgical Oncology 31(4):2414−24

Chen SH, Xie C. 2024. User-friendly prognostic model for rectal neuroendocrine tumours: in the era of precision management. World Journal of Gastroenterology 30(45):4850−54

Tie SJ, Fan ML, Zhang JY, Yu J, Wu N, et al. 2024. Clinical outcomes after endoscopic resection and the risk of lymph node metastasis in rectal neuroendocrine tumors: a single-center retrospective study. Surgical Endoscopy 38(9):5178−86

Sohn B, Kwon Y, Ryoo SB, Song I, Kwon YH, et al. 2017. Predictive factors for lymph node metastasis and prognostic factors for survival in rectal neuroendocrine tumors. Journal of Gastrointestinal Surgery 21(12):2066−74

Hyun JH, Lee SD, Youk EG, Lee JB, Lee EJ, et al. 2015. Clinical impact of atypical endoscopic features in rectal neuroendocrine tumors. World Journal of Gastroenterology 21(47):13302−308

Yu Q, Zhang Y, Su Y, Zhao Q, Xiong K, et al. 2024. Optimization of endoscopic submucosal dissection and endoscopic mucosal resection strategies for rectal neuroendocrine tumors within 20 mm. American Surgeon 90(6):1176−86

Esposito G, Dell’Unto E, Ligato I, Marasco M, Panzuto F. 2023. The meaning of R1 resection after endoscopic removal of gastric, duodenal and rectal neuroendocrine tumors. Expert Review of Gastroenterology & Hepatology 17(8):785−93

Zouli C, Zisimopoulou E, Chrisoulidou A. 2023. Biomarkers in neuroendocrine neoplasms. Hellenic Journal of Nuclear Medicine 26(Suppl):44−48

Mohamed A, Elhawi M, Trybula M, Elshawy M, Chakrabarti S, et al. 2024. Role of bispecific antibodies in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): review of literature. Clinical Medicine Insights: Oncology 18:1−6

Zhang J, Cao Y, Zhang P, Zhang X, Li J, et al. 2022. Serum biomarker status with a distinctive pattern in prognosis of gastroenteropancreatic neuroendocrine carcinoma. Neuroendocrinology 112(8):733−43

Lin J, Wu Y, Lin Z, Lin X, Wu Q, et al. 2024. Mid-level data fusion strategy based on urinary nucleosides SERS spectra and blood CEA levels for enhanced preoperative detection of lymph node metastasis in colorectal cancer. Analytica Chimica Acta 1332:343360

Luan F, Xu S, Chen K, Chen K, Kang M, et al. 2025. Prognostic effect of CEA, AFP, CA19-9 and CA242 for recurrence/metastasis of gastric cancer following radical gastrectomy. Molecular and Clinical Oncology 22(2):17

Kan J, Tian Y, Shao Y, Xu H, Li X, et al. 2022. Role of the ratio of NSE serum concentration in evaluating the therapeutic effect on metastatic neuroendocrine neoplasms of the liver. Tumori 108(2):157−64

Sorbye H, Hjortland GO, Vestermark LW, Sundlov A, Assmus J, et al. 2024. NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms. Journal of Neuroendocrinology 36(11):e13428